[go: up one dir, main page]

WO2010003002A3 - Modulation of follicular helper t cells - Google Patents

Modulation of follicular helper t cells Download PDF

Info

Publication number
WO2010003002A3
WO2010003002A3 PCT/US2009/049421 US2009049421W WO2010003002A3 WO 2010003002 A3 WO2010003002 A3 WO 2010003002A3 US 2009049421 W US2009049421 W US 2009049421W WO 2010003002 A3 WO2010003002 A3 WO 2010003002A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
modulation
follicular helper
follicular
helper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/049421
Other languages
French (fr)
Other versions
WO2010003002A2 (en
WO2010003002A9 (en
Inventor
Chen Dong
Roza Nurieva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2010003002A2 publication Critical patent/WO2010003002A2/en
Publication of WO2010003002A3 publication Critical patent/WO2010003002A3/en
Publication of WO2010003002A9 publication Critical patent/WO2010003002A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/204IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods of modulating the differentiation of Tf1, cells by administering an effective amount of an agonist and/or antagonist of IL-6, IL-21, or STAT3.
PCT/US2009/049421 2008-07-02 2009-07-01 Modulation of follicular helper t cells Ceased WO2010003002A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7782108P 2008-07-02 2008-07-02
US61/077,821 2008-07-02

Publications (3)

Publication Number Publication Date
WO2010003002A2 WO2010003002A2 (en) 2010-01-07
WO2010003002A3 true WO2010003002A3 (en) 2010-04-22
WO2010003002A9 WO2010003002A9 (en) 2010-05-20

Family

ID=41466595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049421 Ceased WO2010003002A2 (en) 2008-07-02 2009-07-01 Modulation of follicular helper t cells

Country Status (1)

Country Link
WO (1) WO2010003002A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967005B2 (en) 2013-03-15 2021-04-06 Celgene Corporation Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
US11130820B2 (en) 2012-12-20 2021-09-28 Celgene Corporation Chimeric antigen receptors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063875A1 (en) 2010-11-11 2012-05-18 シスメックス株式会社 Markers for detecting human follicular helper t cells and method for detecting human follicular helper t cells
US9226936B2 (en) 2011-10-28 2016-01-05 The Wistar of Anatomy and Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
WO2013158290A1 (en) * 2012-04-20 2013-10-24 The Wistar Institute Of Anatomy And Biology Methods and compositions for manipulating the immune system
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
EP3194579A4 (en) * 2014-08-12 2018-04-04 Anthrogenesis Corporation Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
CA3005899A1 (en) * 2015-11-23 2017-06-01 President And Fellows Of Harvard College Compositions and methods for modulating an immune response

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BREITFELD, D. ET AL.: "Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production", J. EXP. MED., vol. 192, no. 11, 2000, pages 1545 - 1551 *
CHTANOVA, T. ET AL.: "T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Thl/Th2 effector cells that provide help for B cells", J. IMMUNOL., vol. 173, 2004, pages 68 - 78 *
KORN, T. ET AL.: "IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells", NATURE, vol. 448, 2007, pages 484 - 488 *
YANG, X. 0. ET AL.: "STAT3 regulates cytokine-mediated generation of inflammatory helper T cells", J. BIOL. CHEM., vol. 282, no. 13, 2007, pages 9358 - 9363 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11130820B2 (en) 2012-12-20 2021-09-28 Celgene Corporation Chimeric antigen receptors
US10967005B2 (en) 2013-03-15 2021-04-06 Celgene Corporation Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
US11806365B2 (en) 2013-03-15 2023-11-07 Celgene Corporation Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis

Also Published As

Publication number Publication date
WO2010003002A2 (en) 2010-01-07
WO2010003002A9 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
WO2010003002A3 (en) Modulation of follicular helper t cells
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
WO2009092087A3 (en) Selective differentiation, identification, and modulation of human th17 cells
EP4509163A3 (en) Graft anchor devices, systems, and methods
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2012018499A3 (en) Specific regulation of cytokine levels by hdac6 inhibitors
WO2012020006A3 (en) Anti-fap antibodies and methods of use
MX340323B (en) In-situ gel forming compositions.
MX2010002028A (en) Methods and compositions for modulating t cells.
WO2009117482A8 (en) Mtor inhibitor salt forms
GEP20135800B (en) Method of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives preparation
UA104438C2 (en) Method for the preparation of dabigatran and its intermediates
JO2822B1 (en) kinase INHIBITORS 6s 70AKT AND P
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
TW200624426A (en) BACE inhibitors
DOP2010000216A (en) (R) -2- (4-CYCLOPROPANSULPHONYL-PHENYL) -N-PIRAZIN-2-IL-3- (TETRAHYDROPIRAN-4-IL) -PROPIONAMIDE CRYSTALLINE
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
MY161601A (en) Films and compositions comprising the same
WO2009146099A3 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
MX2011008816A (en) Improved-scent ectoparasiticidal formulation.
WO2011083483A3 (en) Method for treatment of inflammatory disease and disorder
WO2009152167A3 (en) Delivery of therapeutics
WO2009154739A3 (en) Smoothened receptor modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774452

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09774452

Country of ref document: EP

Kind code of ref document: A2